-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compilenewborn
The American Association for Cancer Research (AACR) 2021 Annual Meeting will be held on April 10-15, 2021.
Uveal melanoma is generally rare, but it is the most common eye cancer in adults, accounting for about 3-5% of all melanomas.
Tebentafusp is a new type of bispecific fusion protein, which is formed by fusion of soluble TCR and anti-CD3 immune effector domain.
In the phase 3 clinical study announced at the meeting, 378 patients with previously untreated metastatic uveal melanoma were randomly assigned at a ratio of 2:1 to receive tebentafusp or a regimen selected by the investigator for first-line treatment.
The results showed that after a median follow-up of 14.
In this study, adverse events related to tebentafusp treatment were predictable and controllable.
As there is currently no standard treatment for patients with uveal metastatic melanoma.
Article reference source:
Bispecific Fusion Protein Tebentafusp Significantly Improves Overall Survival in Patients With Metastatic Uveal Melanoma